This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
Skeletal Muscle Open Access 20 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Deninger M, Goldman J, Melo J . The molecular biology of chronic myelogenous leukemia. Blood 2000; 96: 3343–3356.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
Kantarjian H, Sawyers CL, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.
Ebnoether M, Stentoft J, Ford J, Buhl L, Gratwohl A . Cerebral oedema as a possible complication of treatment with imatinib. Lancet 2002; 359: 1751–1752.
Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002; 95: 881–887.
May DA, Disler DR, Jones EA, Balkisson AA, Manaster BL . Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls. Radiographics 2000; 20: S295–S315.
Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929–2934.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shimazaki, C., Ochiai, N., Uchida, R. et al. Intramuscular edema as a complication of treatment with imatinib. Leukemia 17, 804–805 (2003). https://doi.org/10.1038/sj.leu.2402868
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402868
This article is cited by
-
Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment
International Journal of Hematology (2023)
-
Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
Skeletal Muscle (2018)
-
Medikamenteninduzierte Myopathien
Der Nervenarzt (2006)